Company / EPS (Basic)
Serina Therapeutics, Inc. EPS (Basic) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$1.51
FY2025
5-year range
-$9.70 / $2.36
FY2022-FY2025
Trend
-164.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-9.70 to $-1.51 over the past 2 years.
Based on SEC 10-K filings.
-1.51 in FY2025.
Improved from $-9.70 to $-1.51 over the past 2 years.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (basic) decreased 164.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.51 | -164.0% |
| FY2024 | $2.36 | +124.3% |
| FY2023 | -$9.70 | -4117.4% |
| FY2022 | -$0.23 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026